Research graph
References from Effects of Liraglutide and Semaglutide on Cardiometabolic Dysregulation and Oxidative Stress in an Experimental Model of Metabolic Syndrome. Local targets link to admitted publications; unresolved targets remain external evidence.
10.3390/ijms24097898
10.3390/ijms24097898 · External reference
10.3390/antiox9030236
10.3390/antiox9030236 · External reference
Oxidative Stress: A Unifying Paradigm in Hypertension
2020 · External reference
10.3390/medicina58040472
10.3390/medicina58040472 · External reference
Atherosclerosis: Known and Unknown
10.1111/pin.13202 · 2022 · External reference
Unresolved reference
External reference
Myocardial ‘No-Reflow’—Diagnosis, Pathophysiology and Treatment
10.1016/j.ijcard.2012.12.049 · 2013 · External reference
Evolving Therapies for Myocardial Ischemia/Reperfusion Injury
10.1016/j.jacc.2015.02.032 · 2015 · External reference
Integrative simulation analysis of myocardial ischaemia-reperfusion injury
10.1113/jp290440 · 2026 · External reference
Role of Hyperinsulinemia and Insulin Resistance in Hypertension: Metabolic Syndrome Revisited
2020 · External reference
10.3389/fendo.2025.1614726
10.3389/fendo.2025.1614726 · External reference
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
10.1016/j.cmet.2018.03.001 · 2018 · External reference
GLP-1 Physiology Informs the Pharmacotherapy of Obesity
10.1016/j.molmet.2021.101351 · 2022 · External reference
10.1016/j.jhepr.2026.101993
10.1016/j.jhepr.2026.101993 · External reference
10.3390/jcm14196758
10.3390/jcm14196758 · External reference
10.3390/ijms21239100
10.3390/ijms21239100 · External reference
Effects of Liraglutide on Metabolic Syndrome in WBN/Kob Diabetic Fatty Rats Supplemented with a High-fat Diet
10.1002/ame2.12106 · 2020 · External reference
Semaglutide Attenuates Excessive Exercise-Induced Myocardial Injury through Inhibiting Oxidative Stress and Inflammation in Rats
10.1016/j.lfs.2020.117531 · 2020 · External reference
10.3390/ijms20010006
10.3390/ijms20010006 · External reference
10.3389/fcvm.2023.1208370
10.3389/fcvm.2023.1208370 · External reference
Development of Rat Metabolic Syndrome Models: A Review
10.14202/vetworld.2021.1774-1783 · 2021 · External reference
Towards Standardization of Echocardiography for the Evaluation of Left Ventricular Function in Adult Rodents: A Position Paper of the ESC Working Group on Myocardial Function
10.1093/cvr/cvaa110 · 2021 · External reference
Protective Effects of Galium verum L. Extract against Cardiac Ischemia/Reperfusion Injury in Spontaneously Hypertensive Rats
10.1155/2019/4235405 · 2019 · External reference
Red-Koji Fermented Red Ginseng Ameliorates High Fat Diet-Induced Metabolic Disorders in Mice
10.3390/nu5114316 · 2013 · External reference
Liraglutide, a Human Glucagon-like Peptide-1 Analogue, Stimulates AKT-dependent Survival Signalling and Inhibits Pancreatic Β-cell Apoptosis
10.1111/jcmm.13259 · 2018 · External reference
The Global Epidemic of the Metabolic Syndrome
10.1007/s11906-018-0812-z · 2018 · External reference
10.3390/ijms23084334
10.3390/ijms23084334 · External reference
Once-Weekly Semaglutide in Adults with Overweight or Obesity
10.1056/nejmoa2032183 · 2021 · External reference
Weight Loss with Subcutaneous Semaglutide versus Other Glucagon-like Peptide 1 Receptor Agonists in Type 2 Diabetes: A Systematic Review
10.1111/imj.16126 · 2023 · External reference
Semaglutide Lowers Body Weight in Rodents via Distributed Neural Pathways
10.1172/jci.insight.133429 · 2020 · External reference
Comparative Effectiveness of GLP-1 Receptor Agonists on Glycaemic Control, Body Weight, and Lipid Profile for Type 2 Diabetes: Systematic Review and Network Meta-Analysis
10.1136/bmj-2023-076410 · 2024 · External reference
10.3390/ijms241210164
10.3390/ijms241210164 · External reference
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis
10.1016/j.eprac.2023.11.007 · 2024 · External reference
Liraglutide Improves Lipid Metabolism by Enhancing Cholesterol Efflux Associated with ABCA1 and ERK1/2 Pathway
10.1186/s12933-019-0954-6 · 2019 · External reference
Glucagon-like Peptide-1 Receptor Agonists Modestly Reduced Blood Pressure among Patients with and without Diabetes Mellitus: A Meta-analysis and Meta-regression
10.1111/dom.15529 · 2024 · External reference
The Role of Glucagon-like Peptide-1 Receptor Agonists (GLP1-RAs) in the Management of the Hypertensive Patient with Metabolic Syndrome: A Position Paper from the Korean Society of Hypertension
10.1186/s40885-024-00279-4 · 2024 · External reference
Glucagon-like Peptide 1 Treatment Reverses Vascular Remodelling by Downregulating Matrix Metalloproteinase 1 Expression through Inhibition of the ERK1/2/NF-κB Signalling Pathway
10.1016/j.mce.2020.111005 · 2020 · External reference
The Blood Pressure Lowering Effects of Glucagon-like Peptide-1 Receptor Agonists: A Mini-Review of the Potential Mechanisms
10.1016/j.coph.2023.102355 · 2023 · External reference
GLP-1 Receptor Agonists and Blood Pressure: A State-of-the-Art Review of Mechanisms, Evidence, and Clinical Implications
10.1093/ajh/hpaf205 · 2026 · External reference
Glucagon-Like Peptide-1 Analog Liraglutide Attenuates Pressure-Overload Induced Cardiac Hypertrophy and Apoptosis through Activating ATP Sensitive Potassium Channels
10.1007/s10557-020-07088-5 · 2021 · External reference
Glucagon-like Peptide-1 Receptor Agonist Treatment of High Carbohydrate Intake-induced Metabolic Syndrome Provides Pleiotropic Effects on Cardiac Dysfunction through Alleviations in Electrical and Intracellular Ca2+ Abnormalities and Mitochondrial Dysfunction
10.1111/1440-1681.13590 · 2022 · External reference
Semaglutide Inhibits Ischemia/Reperfusion-Induced Cardiomyocyte Apoptosis through Activating PKG/PKCε/ERK1/2 Pathway
10.1016/j.bbrc.2023.01.049 · 2023 · External reference
Liraglutide Prevents and Reverses Monocrotaline-Induced Pulmonary Arterial Hypertension by Suppressing ET-1 and Enhancing eNOS/sGC/PKG Pathways
10.1038/srep31788 · 2016 · External reference
Exenatide Prevents Morphological and Structural Changes of Mitochondria Following Ischaemia-Reperfusion Injury
10.1016/j.hlc.2016.08.007 · 2017 · External reference
Long-Term Activation of Glucagon-like Peptide-1 Receptor by Dulaglutide Prevents Diabetic Heart Failure and Metabolic Remodeling in Type 2 Diabetes
10.1161/jaha.122.026728 · 2022 · External reference
Superoxide Dismutase Nanozymes: An Emerging Star for Anti-Oxidation
10.1039/d1tb00720c · 2021 · External reference
Exploring the Antioxidant Properties of Semaglutide: A Comprehensive Review
10.1016/j.jdiacomp.2024.108906 · 2024 · External reference
10.3389/fphar.2024.1353029
10.3389/fphar.2024.1353029 · External reference
Comparison of Effects of Injectable Semaglutide and Dulaglutide on Oxidative Stress and Glucose Variability in Patients with Type 2 Diabetes Mellitus: A Prospective Preliminary Study
10.1007/s13300-023-01493-3 · 2024 · External reference
Peroxiredoxin 2, Glutathione Peroxidase, and Catalase in the Cytosol and Membrane of Erythrocytes under H2 O2 -Induced Oxidative Stress
10.3109/10715762.2015.1028402 · 2015 · External reference
Cardioprotective Effects of Liraglutide Pretreatment on Isoprenaline-Induced Myocardial Injury in Rats
10.1139/cjpp-2022-0534 · 2023 · External reference
Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus
10.1016/j.jcjd.2019.09.003 · 2020 · External reference
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
10.1056/nejmoa1603827 · 2016 · External reference
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
10.1056/nejmoa1607141 · 2016 · External reference
10.3390/ijms24021703
10.3390/ijms24021703 · External reference
Incretins (GLP-1 Receptor Agonists and Dual/Triple Agonists) and the Liver
10.1016/j.jhep.2023.07.033 · 2023 · External reference
Hepatic Microcirculation in Fatty Liver Disease
10.1002/ar.20715 · 2008 · External reference
Hepatoprotective Effects of Semaglutide, Lanifibranor and Dietary Intervention in the GAN Diet-induced Obese and Biopsy-confirmed Mouse Model of NASH
10.1111/cts.13235 · 2022 · External reference
GLP-1 Derivative Liraglutide in Rats with β-cell Deficiencies: Influence of Metabolic State on β-cell Mass Dynamics
10.1038/sj.bjp.0705397 · 2003 · External reference
Pancreatic Islet Cells Disarray, Apoptosis, and Proliferation in Obese Mice. The Role of Semaglutide Treatment
10.1016/j.biochi.2021.10.017 · 2022 · External reference
Glucagon-like Peptide-1 Receptor Agonist Treatment Reduces Beta Cell Mass in Normoglycaemic Mice
10.1007/s00125-013-2957-2 · 2013 · External reference
Effects of Liraglutide on Metabolic Syndrome in WBN/Kob Diabetic Fatty Rats Supplemented with a High-fat Diet
10.1002/ame2.12106 · ExternalCitation · doi-reference
Hepatic Microcirculation in Fatty Liver Disease
10.1002/ar.20715 · ExternalCitation · doi-reference
Glucagon-like Peptide-1 Receptor Agonist Treatment Reduces Beta Cell Mass in Normoglycaemic Mice
10.1007/s00125-013-2957-2 · ExternalCitation · doi-reference
Glucagon-Like Peptide-1 Analog Liraglutide Attenuates Pressure-Overload Induced Cardiac Hypertrophy and Apoptosis through Activating ATP Sensitive Potassium Channels
10.1007/s10557-020-07088-5 · ExternalCitation · doi-reference
The Global Epidemic of the Metabolic Syndrome
10.1007/s11906-018-0812-z · ExternalCitation · doi-reference
Comparison of Effects of Injectable Semaglutide and Dulaglutide on Oxidative Stress and Glucose Variability in Patients with Type 2 Diabetes Mellitus: A Prospective Preliminary Study
10.1007/s13300-023-01493-3 · ExternalCitation · doi-reference
Semaglutide Inhibits Ischemia/Reperfusion-Induced Cardiomyocyte Apoptosis through Activating PKG/PKCε/ERK1/2 Pathway
10.1016/j.bbrc.2023.01.049 · ExternalCitation · doi-reference
Pancreatic Islet Cells Disarray, Apoptosis, and Proliferation in Obese Mice. The Role of Semaglutide Treatment
10.1016/j.biochi.2021.10.017 · ExternalCitation · doi-reference
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
10.1016/j.cmet.2018.03.001 · ExternalCitation · doi-reference
The Blood Pressure Lowering Effects of Glucagon-like Peptide-1 Receptor Agonists: A Mini-Review of the Potential Mechanisms
10.1016/j.coph.2023.102355 · ExternalCitation · doi-reference
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis
10.1016/j.eprac.2023.11.007 · ExternalCitation · doi-reference
Exenatide Prevents Morphological and Structural Changes of Mitochondria Following Ischaemia-Reperfusion Injury
10.1016/j.hlc.2016.08.007 · ExternalCitation · doi-reference
Myocardial ‘No-Reflow’—Diagnosis, Pathophysiology and Treatment
10.1016/j.ijcard.2012.12.049 · ExternalCitation · doi-reference
Evolving Therapies for Myocardial Ischemia/Reperfusion Injury
10.1016/j.jacc.2015.02.032 · ExternalCitation · doi-reference
Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus
10.1016/j.jcjd.2019.09.003 · ExternalCitation · doi-reference
Exploring the Antioxidant Properties of Semaglutide: A Comprehensive Review
10.1016/j.jdiacomp.2024.108906 · ExternalCitation · doi-reference
Incretins (GLP-1 Receptor Agonists and Dual/Triple Agonists) and the Liver
10.1016/j.jhep.2023.07.033 · ExternalCitation · doi-reference
10.1016/j.jhepr.2026.101993
10.1016/j.jhepr.2026.101993 · ExternalCitation · doi-reference
Semaglutide Attenuates Excessive Exercise-Induced Myocardial Injury through Inhibiting Oxidative Stress and Inflammation in Rats
10.1016/j.lfs.2020.117531 · ExternalCitation · doi-reference
Glucagon-like Peptide 1 Treatment Reverses Vascular Remodelling by Downregulating Matrix Metalloproteinase 1 Expression through Inhibition of the ERK1/2/NF-κB Signalling Pathway
10.1016/j.mce.2020.111005 · ExternalCitation · doi-reference
GLP-1 Physiology Informs the Pharmacotherapy of Obesity
10.1016/j.molmet.2021.101351 · ExternalCitation · doi-reference
GLP-1 Derivative Liraglutide in Rats with β-cell Deficiencies: Influence of Metabolic State on β-cell Mass Dynamics
10.1038/sj.bjp.0705397 · ExternalCitation · doi-reference
Liraglutide Prevents and Reverses Monocrotaline-Induced Pulmonary Arterial Hypertension by Suppressing ET-1 and Enhancing eNOS/sGC/PKG Pathways
10.1038/srep31788 · ExternalCitation · doi-reference
Superoxide Dismutase Nanozymes: An Emerging Star for Anti-Oxidation
10.1039/d1tb00720c · ExternalCitation · doi-reference
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
10.1056/nejmoa1603827 · ExternalCitation · doi-reference
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
10.1056/nejmoa1607141 · ExternalCitation · doi-reference
Once-Weekly Semaglutide in Adults with Overweight or Obesity
10.1056/nejmoa2032183 · ExternalCitation · doi-reference
GLP-1 Receptor Agonists and Blood Pressure: A State-of-the-Art Review of Mechanisms, Evidence, and Clinical Implications
10.1093/ajh/hpaf205 · ExternalCitation · doi-reference
Towards Standardization of Echocardiography for the Evaluation of Left Ventricular Function in Adult Rodents: A Position Paper of the ESC Working Group on Myocardial Function
10.1093/cvr/cvaa110 · ExternalCitation · doi-reference
Glucagon-like Peptide-1 Receptor Agonist Treatment of High Carbohydrate Intake-induced Metabolic Syndrome Provides Pleiotropic Effects on Cardiac Dysfunction through Alleviations in Electrical and Intracellular Ca2+ Abnormalities and Mitochondrial Dysfunction
10.1111/1440-1681.13590 · ExternalCitation · doi-reference
Hepatoprotective Effects of Semaglutide, Lanifibranor and Dietary Intervention in the GAN Diet-induced Obese and Biopsy-confirmed Mouse Model of NASH
10.1111/cts.13235 · ExternalCitation · doi-reference
Glucagon-like Peptide-1 Receptor Agonists Modestly Reduced Blood Pressure among Patients with and without Diabetes Mellitus: A Meta-analysis and Meta-regression
10.1111/dom.15529 · ExternalCitation · doi-reference
Weight Loss with Subcutaneous Semaglutide versus Other Glucagon-like Peptide 1 Receptor Agonists in Type 2 Diabetes: A Systematic Review
10.1111/imj.16126 · ExternalCitation · doi-reference
Liraglutide, a Human Glucagon-like Peptide-1 Analogue, Stimulates AKT-dependent Survival Signalling and Inhibits Pancreatic Β-cell Apoptosis
10.1111/jcmm.13259 · ExternalCitation · doi-reference
Atherosclerosis: Known and Unknown
10.1111/pin.13202 · ExternalCitation · doi-reference
Integrative simulation analysis of myocardial ischaemia-reperfusion injury
10.1113/jp290440 · ExternalCitation · doi-reference
Comparative Effectiveness of GLP-1 Receptor Agonists on Glycaemic Control, Body Weight, and Lipid Profile for Type 2 Diabetes: Systematic Review and Network Meta-Analysis
10.1136/bmj-2023-076410 · ExternalCitation · doi-reference
Cardioprotective Effects of Liraglutide Pretreatment on Isoprenaline-Induced Myocardial Injury in Rats
10.1139/cjpp-2022-0534 · ExternalCitation · doi-reference
Protective Effects of Galium verum L. Extract against Cardiac Ischemia/Reperfusion Injury in Spontaneously Hypertensive Rats
10.1155/2019/4235405 · ExternalCitation · doi-reference
Long-Term Activation of Glucagon-like Peptide-1 Receptor by Dulaglutide Prevents Diabetic Heart Failure and Metabolic Remodeling in Type 2 Diabetes
10.1161/jaha.122.026728 · ExternalCitation · doi-reference
Semaglutide Lowers Body Weight in Rodents via Distributed Neural Pathways
10.1172/jci.insight.133429 · ExternalCitation · doi-reference
Liraglutide Improves Lipid Metabolism by Enhancing Cholesterol Efflux Associated with ABCA1 and ERK1/2 Pathway
10.1186/s12933-019-0954-6 · ExternalCitation · doi-reference
The Role of Glucagon-like Peptide-1 Receptor Agonists (GLP1-RAs) in the Management of the Hypertensive Patient with Metabolic Syndrome: A Position Paper from the Korean Society of Hypertension
10.1186/s40885-024-00279-4 · ExternalCitation · doi-reference
Development of Rat Metabolic Syndrome Models: A Review
10.14202/vetworld.2021.1774-1783 · ExternalCitation · doi-reference
Peroxiredoxin 2, Glutathione Peroxidase, and Catalase in the Cytosol and Membrane of Erythrocytes under H2 O2 -Induced Oxidative Stress
10.3109/10715762.2015.1028402 · ExternalCitation · doi-reference
10.3389/fcvm.2023.1208370
10.3389/fcvm.2023.1208370 · ExternalCitation · doi-reference
10.3389/fendo.2025.1614726
10.3389/fendo.2025.1614726 · ExternalCitation · doi-reference
10.3389/fphar.2024.1353029
10.3389/fphar.2024.1353029 · ExternalCitation · doi-reference
10.3390/antiox9030236
10.3390/antiox9030236 · ExternalCitation · doi-reference
10.3390/ijms20010006
10.3390/ijms20010006 · ExternalCitation · doi-reference
10.3390/ijms21239100
10.3390/ijms21239100 · ExternalCitation · doi-reference
10.3390/ijms23084334
10.3390/ijms23084334 · ExternalCitation · doi-reference
10.3390/ijms24021703
10.3390/ijms24021703 · ExternalCitation · doi-reference
10.3390/ijms24097898
10.3390/ijms24097898 · ExternalCitation · doi-reference
10.3390/ijms241210164
10.3390/ijms241210164 · ExternalCitation · doi-reference
10.3390/jcm14196758
10.3390/jcm14196758 · ExternalCitation · doi-reference
10.3390/medicina58040472
10.3390/medicina58040472 · ExternalCitation · doi-reference
Red-Koji Fermented Red Ginseng Ameliorates High Fat Diet-Induced Metabolic Disorders in Mice
10.3390/nu5114316 · ExternalCitation · doi-reference
